[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Aloysius MM, Zaitoun AM, Bates TE, Ilyas M, Constantin-Teodosiu D, Rowlands BJ, Lobo DN: Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer? BMC Cancer; 2010;10:80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?
  • METHODS: This was a retrospective study on tissue microarrays constructed from formalin-fixed paraffin-embedded tissue from 126 consecutive patients (cancer = 104, chronic pancreatitis = 22) undergoing pancreatic resections between June 2001 and June 2006.
  • 78 specimens of chronic pancreatitis tissue were obtained adjacent to areas of cancer.
  • Normal pancreatic tissue was obtained from the resection specimens in a total of 30 patients.
  • RESULTS: MMCs I, III, IV and V were highly expressed (p < 0.05) in all primary periampullary cancers compared with metastatic lymph nodes and adjacent benign pancreas.
  • MMCs III, IV and V were highly expressed in all cancers regardless of type compared with chronic pancreatitis (p < 0.05).
  • CONCLUSIONS: Differential expression of MMCs III, IV and V in primary periampullary cancers compared with adjacent benign periampullary tissue and chronic pancreatitis is a novel finding, which may render them attractive anticancer targets.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Immunohistochemistry / methods. Mitochondria / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Epithelium / drug effects. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Oxidative Stress. Pancreas / pathology. Pancreatitis / pathology. Phosphorylation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 18;289(5482):1150-1 [10970229.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):9-19 [11678313.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Nov 1;176(3):145-52 [11714246.001]
  • [Cites] Cell. 2003 Feb 21;112(4):481-90 [12600312.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L189-98 [12665464.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):372-8 [15310457.001]
  • [Cites] BMJ. 2004 Sep 18;329(7467):668-73 [15374918.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3641-7 [8252480.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 11;328(2):623-32 [15694394.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 1;70(1):1-12 [15907809.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):401-8 [16054089.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4787-97 [16892091.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4812-30 [16892093.001]
  • [Cites] Exp Physiol. 2006 Sep;91(5):807-19 [16857720.001]
  • [Cites] FEBS Lett. 2006 Oct 2;580(22):5125-9 [16979626.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):50-5 [17214968.001]
  • [Cites] J Bioenerg Biomembr. 2007 Feb;39(1):65-72 [17294131.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 [17475665.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 7;364(1):131-7 [17931597.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1593-600 [19223492.001]
  • [Cites] BMC Cancer. 2009;9:327 [19754967.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):72-6 [11120486.001]
  • (PMID = 20202214.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2841142
  •  go-up   go-down


2. Home PD, Lagarenne P: Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia; 2009 Dec;52(12):2499-506
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS/HYPOTHESIS: Recent publications of data extracted from population registries have suggested a possible relationship between treatment with insulin glargine and increased incidence of cancer/breast cancer.
  • METHODS: We analysed the manufacturer's (sanofi-aventis) pharmacovigilance database for all randomised clinical trials (RCTs; Phase 2-4) comparing insulin glargine with any comparator in type 1 or type 2 diabetes.
  • We identified all serious adverse events coded under the System Organ Class of 'neoplasms, benign, malignant and unspecified'.
  • Treatment-emergent neoplasms judged to be malignant were included in this analysis.
  • RESULTS: The database included 31 studies, 12 in type 1 diabetes and 19 in type 2 diabetes.
  • Skin (12 people with 16 events vs six people with seven events, RR 1.85, 95% CI 0.69-4.92), colon and rectum (six vs ten people, RR 0.55, 95% CI 0.20-1.52), breast (four vs six people, RR 0.62, 95% CI 0.17-2.18) and gastrointestinal tract (six vs four people, RR 1.38, 95% CI 0.39-4.90) were the most commonly reported sites.
  • [MeSH-major] Diabetes Mellitus, Type 1 / drug therapy. Diabetes Mellitus, Type 2 / drug therapy. Insulin / analogs & derivatives. Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Databases, Factual. Female. Humans. Hypoglycemic Agents / adverse effects. Hypoglycemic Agents / therapeutic use. Incidence. Insulin Glargine. Insulin, Isophane / therapeutic use. Insulin, Long-Acting. Male. Middle Aged. Random Allocation. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes Res Clin Pract. 2007 Apr;76(1):111-8 [17011662.001]
  • [Cites] Lancet. 2008 Mar 29;371(9618):1073-84 [18374840.001]
  • [Cites] J Pediatr. 2008 Oct;153(4):547-53 [18589448.001]
  • [Cites] Diabetes Obes Metab. 2009 Apr;11(4):379-86 [19087105.001]
  • [Cites] Drug Saf. 2009;32(3):187-202 [19338377.001]
  • [Cites] Lancet. 2009 Jun 20;373(9681):2125-35 [19501900.001]
  • [Cites] Diabetes Care. 2009 Jul;32(7):1170-6 [19389820.001]
  • [Cites] Diabetologia. 2009 Sep;52(9):1778-88 [19526210.001]
  • [Cites] Diabetologia. 2009 Sep;52(9):1732-44 [19565214.001]
  • [Cites] Diabetologia. 2009 Sep;52(9):1766-77 [19572116.001]
  • [Cites] Diabetologia. 2009 Sep;52(9):1745-54 [19588120.001]
  • [Cites] Diabetologia. 2009 Sep;52(9):1755-65 [19603149.001]
  • [Cites] Diabetologia. 2009 Sep;52(9):1971-3 [19609501.001]
  • [Cites] Obes Rev. 2009 Nov;10(6):610-6 [19527447.001]
  • [Cites] Diabetes Care. 2000 May;23(5):639-43 [10834423.001]
  • [Cites] Diabetes Care. 2000 Feb;23(2):157-62 [10868824.001]
  • [Cites] Diabetes Care. 2000 Aug;23(8):1137-42 [10937511.001]
  • [Cites] Diabetes Care. 2000 Nov;23(11):1666-71 [11092290.001]
  • [Cites] Diabetes Care. 2001 Apr;24(4):631-6 [11315821.001]
  • [Cites] J Pediatr Endocrinol Metab. 2002 Apr;15(4):369-76 [12008682.001]
  • [Cites] Diabetes Care. 2003 Mar;26(3):799-804 [12610040.001]
  • [Cites] Horm Metab Res. 2003 Mar;35(3):189-96 [12734781.001]
  • [Cites] Ann Intern Med. 2003 Jun 17;138(12):952-9 [12809451.001]
  • [Cites] Diabet Med. 2003 Jul;20(7):545-51 [12823235.001]
  • [Cites] Diabetes Care. 2003 Nov;26(11):3080-6 [14578243.001]
  • [Cites] Diabetes Care. 2005 Feb;28(2):254-9 [15677775.001]
  • [Cites] Intern Med J. 2005 Sep;35(9):536-42 [16105155.001]
  • [Cites] Diabetes Metab Res Rev. 2005 Nov-Dec;21(6):545-53 [16021649.001]
  • [Cites] Diabetologia. 2006 Mar;49(3):442-51 [16456680.001]
  • [Cites] Diabet Med. 2006 Mar;23(3):285-92 [16492212.001]
  • [Cites] Diabetes Care. 2006 Mar;29(3):554-9 [16505505.001]
  • [Cites] Arch Med Res. 2006 May;37(4):495-501 [16715577.001]
  • [Cites] Diabet Med. 2006 Jul;23(7):736-42 [16842477.001]
  • [CommentIn] Diabetologia. 2010 Apr;53(4):790-2; author reply 793-4 [20099058.001]
  • (PMID = 19756478.001).
  • [ISSN] 1432-0428
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin, Long-Acting; 2ZM8CX04RZ / Insulin Glargine; 53027-39-7 / Insulin, Isophane
  •  go-up   go-down


3. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This multicentre study involved 28 Italian ORL Centres responding to a questionnaire sent by us which allowed recruitment of a high large number of cases of parotid neoplasms observed over a 10-year period.
  • Benign tumours account for 80% of case histories with a relationship 1:4 M/F, the most frequent being pleomorphic adenoma (57.3% of cases), followed by Warthin's tumour (32.4%), this rating not having been confirmed in case histories (8-10%) in the literature.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • Enucleoresection was limited to approximately 15% of neoplasms, enucleation to <10% of cases with only 2% of pleomorph adenoma due to the well-known anatomo-pathological characteristics which may lead to relapse.
  • For malignant neoplasms, total parotidectomy was performed in approximately 50% of cases, while in the remaining 50% an almost equal rate of superficial parotidectomy was carried out and enlarged parotidectomy, with or without sacrificing the facial nerve, which was rebuilt in 60% of cases.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • Sentinel lymph node was observed in a limited number of centres.
  • When no clinically evident lymph nodes were present (NO) considering the tumour histotype, two thirds of patients underwent surgery or radiotherapy, while in the remainder the wait-and-see attitude was prefered.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • [MeSH-major] Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


Advertisement
4. Martínez De Pablo MI, Iranzo P, Mascaró JM, Llambrich A, Baradad M, Herrero C: Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol; 2005;85(3):233-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone.
  • Paraneoplastic pemphigus is a life-threatening autoimmune bullous disease associated with neoplasia, generally of lymphoid origin.
  • Immunosuppressive therapy is often disappointing and there are only a few reports of patients surviving more than 2 years.
  • These cases were generally associated with benign neoplasms.
  • We report here the case of a patient with paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma who had a surprisingly good response to systemic corticosteroids and remains free of lesions more than 3 years later despite progression of her neoplasm.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Paraneoplastic Syndromes / diagnosis. Pemphigus / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Drug Administration Schedule. Female. Glucocorticoids / administration & dosage. Humans. Oral Ulcer / pathology. Prednisone / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040408.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Femia A, Klein PA: Letter: Iatrogenic lipomatosis: a rare manifestation of treatment with a peroxisome proliferator-activated receptor gamma agonist. Dermatol Online J; 2010;16(4):15
Hazardous Substances Data Bank. PIOGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter: Iatrogenic lipomatosis: a rare manifestation of treatment with a peroxisome proliferator-activated receptor gamma agonist.
  • Lipomas are common benign neoplasms of adipose tissue.
  • In one reported case, the development of multiple lipomas occurred as a result of treatment with rosiglitazone, a peroxisome proliferator-activated receptor (PPAR) gamma agonist.
  • We report a second case of lipomatosis occurring as a result of treatment with a PPAR gamma agonist.
  • This case occurred in a 77-year-old woman who developed multiple lipomas two years after beginning treatment with pioglitazone, a PPAR gamma agonist.
  • [MeSH-major] Diabetes Mellitus, Type 2 / drug therapy. Hypoglycemic Agents / adverse effects. Lipoma / chemically induced. Neoplasms, Multiple Primary / chemically induced. PPAR gamma / agonists. Skin Neoplasms / chemically induced. Thiazolidinediones / adverse effects
  • [MeSH-minor] Adipose Tissue / drug effects. Aged. Female. Humans. Iatrogenic Disease

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409422.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; X4OV71U42S / pioglitazone
  •  go-up   go-down


6. Savas A, Erdem A, Tun K, Kanpolat Y: Fatal toxic effect of bleomycin on brain tissue after intracystic chemotherapy for a craniopharyngioma: case report. Neurosurgery; 2000 Jan;46(1):213-6; discussion 216-7
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal toxic effect of bleomycin on brain tissue after intracystic chemotherapy for a craniopharyngioma: case report.
  • OBJECTIVE AND IMPORTANCE: Craniopharyngiomas are benign neoplasms of epithelial origin that arise from the remnants of Rathke's pouch and are located in the sellar, parasellar, and third ventricular regions.
  • Despite major advances in microsurgical techniques, total removal of these tumors is associated with a high risk of death, long-term endocrinological dependence, cognitive dysfunction, and behavioral disorders.
  • Moreover, only a few side effects have been reported for this treatment method.
  • We report a patient with a cystic craniopharyngioma who was treated using intracavitary bleomycin administration and died as a result of the direct toxic effects of bleomycin on deep brain structures and the brainstem.
  • CLINICAL PRESENTATION AND INTERVENTION: A 47-year-old woman with a cystic craniopharyngioma underwent stereotactic insertion of a catheter attached to a subcutaneous reservoir.
  • Five months after the procedure, positive-contrast computed tomographic cystography was performed to confirm the absence of fluid leakage.
  • After the treatment, the cystic cavity regressed but the patient exhibited neurological deterioration; magnetic resonance imaging scans revealed diffuse edema in the diencephalon and brainstem.
  • The patient died 45 days after completion of the treatment.
  • CONCLUSION: Intracavitary administration of bleomycin is not a treatment protocol without risks or side effects, even if there is no fluid leakage into the cerebrospinal fluid.
  • Although this is known to be an effective treatment for cystic craniopharyngiomas, previous reports cannot be used to establish a standard treatment method, and more research is needed to yield a safer effective protocol.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Bleomycin / adverse effects. Brain Edema / chemically induced. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10626953.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


7. Cavaliere R, Lopes MB, Schiff D: Low-grade gliomas: an update on pathology and therapy. Lancet Neurol; 2005 Nov;4(11):760-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade gliomas: an update on pathology and therapy.
  • Low-grade gliomas (LGG) are not benign neoplasms.
  • Although the survival of patients with LGG is better than that of patients with higher-grade tumours, many of the treatments can produce or contribute to chronic impairment, particularly radiotherapy.
  • Chemotherapy has emerged as a promising therapy, although definitive findings are awaited.
  • Breakthroughs in molecular biology have improved our understanding of tumours and have led to the development of novel treatments and better prognoses.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioma / pathology. Glioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239183.001).
  • [ISSN] 1474-4422
  • [Journal-full-title] The Lancet. Neurology
  • [ISO-abbreviation] Lancet Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


8. Velusamy A, Saw S, Gossage J, Bailey S, Schofield J: Combined adenocarcinoid and mucinous cystadenoma of the appendix: a case report. J Med Case Rep; 2009;3:28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Adenocarcinoid of the appendix is a rare malignant tumour with features of both adenocarcinoma and carcinoid, showing both epithelial and endocrine differentiation.
  • Mucinous cystadenoma is the commonest of the benign neoplasms of the appendix, with an incidence of 0.6% in appendicectomy specimens.
  • We report a rare combination of these tumours and discuss the latest treatment options.
  • CASE PRESENTATION: A 71-year-old Caucasian man presented to our department with a right iliac fossa mass associated with pain.
  • Right hemicolectomy is generally advised if any of the following features are present: tumours greater than 2 cm, involvement of resection margins, greater than 2 mitoses/10 high-power fields on histology, extension of tumour beyond serosa.
  • Chemotherapy mostly with 5-Fluorouracil and Leucovorin is advised for remnant disease after surgery.
  • Cytoreductive surgery with intraperitoneal chemotherapy can offer improved survival for advanced peritoneal dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2007 Nov-Dec;93(6):587-90 [18338494.001]
  • [Cites] Histopathology. 2007 Dec;51(6):763-73 [18042066.001]
  • [Cites] Endocr Pathol. 2007 Spring;18(1):16-22 [17652796.001]
  • [Cites] J Gastroenterol. 2006 Aug;41(8):745-9 [16988762.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):52-60 [16794389.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Histopathology. 1995 Dec;27(6):557-62 [8838336.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1436-9 [16136284.001]
  • (PMID = 19171048.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2647933
  •  go-up   go-down


9. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P: Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly; 2004 Mar 20;134(11-12):145-53
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gastrointestinal stromal tumors: from diagnosis to treatment.
  • Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the digestive tract.
  • Most gastrointestinal soft tissue neoplasms, previously classified as leiomyomas, schwannomas, leiomyoblastomas or leiomyosarcomas, are today classified as GIST on the basis of molecular and immunohistological features.
  • They originate from gastrointestinal pacemaker cells and are characterised by over-expression of the tyrosine kinase receptor KIT.
  • However, these tumours span a wide clinical spectrum from benign to highly malignant.
  • Prognostic factors have recently been identified for GIST and include tumour size, mitotic rate and other minor factors.
  • At present, surgery is the standard treatment for primary resectable GIST.
  • Benign GIST have an excellent prognosis after primary surgical treatment, with over 90% 5-year survival.
  • While recurrent or malignant GIST, which are resistant to radiotherapy and chemotherapy, had until recently an extremely poor prognosis even after surgical resection, with median survival of 12 months.
  • The development of a tyrosine kinase inhibitor has changed the management of unresectable malignant cases.
  • This paper reviews the literature and our experience of GIST, including: diagnosis, pathology, treatment and prognosis.
  • [MeSH-major] Gastrointestinal Neoplasms
  • [MeSH-minor] Algorithms. Antineoplastic Agents. Benzamides. Humans. Imatinib Mesylate. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Invasiveness. Piperazines / therapeutic use. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use. Stromal Cells / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106018.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 84
  •  go-up   go-down


10. Hollander CF, Zurcher C, Broerse JJ: Tumorigenesis in high-dose total body irradiated rhesus monkeys--a life span study. Toxicol Pathol; 2003 Mar-Apr;31(2):209-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TBI in combination with chemotherapy, followed by rescue with BMT is increasingly used for the treatment of hematological malignancies and refractory autoimmune disease.
  • The risk of radiation carcinogenesis after this treatment is of growing concern in man.
  • Studies on tumor induction in nonhuman primates are of relevance in this context since the response of this species to radiation does not differ much from that in man.
  • The group of long-term surviving monkeys comprised nine neutron irradiated animals (average total body dose 3A Gy, range 2.3-4.4 Gy) and 20 X-irradiated monkeys (average total body dose 7.1 Gy, range 2.8-8.6 Gy).
  • All animals wereregularly screened for the occurrence of tumors.
  • At postirradiation intervals of 4-21 years an appreciable number of malignant tumors was observed.
  • In the neutron irradiated group eight out of nine animals died with 1 or more malignant tumors.
  • The tumors in the control group, in seven out of 21 animals, appeared at much older age compared with those in the irradiated cohorts.
  • The histogenesis of the malignant tumors was diverse, as was the case for benign tumors.
  • The observed shortening of latency periods and life span, as well as, the increase of mean number of tumors per tumor bearing animal for benign neoplasms parallels the trend observed for malignant tumors.
  • The results of this study were compared to other radiation late effects after TBI followed by different BMT treatment modalities in Rhesus monkeys.
  • The observation that the carcinogenic risk of TBI in the Rhesus monkeys is similar to that derived from the studies of the Japanese atomic bomb survivors and the increase of the risk by a factor of 8 emphasizes the need for regular screening for secondary radiation-induced tumors in long-term surviving patients after TBI followed by BMT.
  • [MeSH-major] Macaca mulatta. Monkey Diseases / etiology. Neoplasms, Radiation-Induced / etiology. Radiation Injuries, Experimental / etiology. Whole-Body Irradiation / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12696581.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Paulino AC, Wen BC, Brown CK, Tannous R, Mayr NA, Zhen WK, Weidner GJ, Hussey DH: Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1239-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects in children treated with radiation therapy for Wilms' tumor.
  • PURPOSE: To determine the frequency and types of late effects in children receiving radiation therapy (RT) for Wilms' tumor.
  • MATERIALS AND METHODS: From 1968 to 1994, 55 children received megavoltage RT at our institution as part of treatment for Wilms' tumor.
  • There were 25 female and 17 male patients with a median age at diagnosis of 48 months (range, 7-126 months).
  • Whole-lung RT was delivered to 13 patients either at diagnosis or pulmonary relapse.
  • All patients received chemotherapy; the most common agents were actinomycin-D/vincristine/adriamycin in 13 and actinomycin-D/vincristine in 18.
  • RESULTS: Of 42 patients, 13 (31.0%) did not have late effects of treatment.
  • The number of patients who developed muscular hypoplasia, limb length inequality, kyphosis, and iliac wing hypoplasia were seven (16.7%), five (11.9%), three (7.1%), and three (7.1%), respectively.
  • Median time to development of scoliosis was 102 months, with a range of 16-146 months.
  • Only one of 12 Group A patients developed scoliosis.
  • The 10- and 15-year actuarial incidences of scoliosis for Group A and B patients were 37.7 +/- 12.4% and 37.7 +/- 12.4%, whereas for Group C patients the incidences were 65.8 +/- 12.0% and 74.4 +/- 11.
  • Of 23 patients, five irradiated within 10 days of surgery and one of 19 irradiated after 10 days developed bowel obstruction (p = 0.09, log rank test).
  • Three patients developed hypertension with normal blood urea nitrogen (BUN) and creatinine levels; another patient had chronic renal insufficiency in a nonirradiated kidney.
  • One patient developed diffuse interstitial pneumonitis.
  • Four patients developed benign neoplasms; three were in the RT field (two osteochondroma, one lipoma) and one outside (cervical intraepithelial neoplasia II).
  • There were three second malignancies (chronic myelogenous leukemia at 9 years, osteosarcoma at 11 years, and breast cancer at 25 years after initial diagnosis of nephroblastoma); both solid malignancies occurred in the RT field.
  • CONCLUSIONS: Late effects of therapy were seen in more than two thirds of children treated for Wilms' tumor.
  • [MeSH-major] Kidney Neoplasms / radiotherapy. Radiation Injuries / complications. Wilms Tumor / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Fertility / radiation effects. Follow-Up Studies. Humans. Infant. Intestinal Obstruction / etiology. Intestine, Small / radiation effects. Kidney Diseases / etiology. Kyphosis / etiology. Male. Muscles / radiation effects. Neoplasm Staging. Neoplasms, Second Primary / etiology. Puberty, Delayed / etiology. Scoliosis / etiology. Time Factors

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725637.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


12. Rosato L, Mondini G, Serbelloni M, Bertone P, Orlassino R, Cossavella D: [Intra-abdominal desmoid tumors: rare but important disease]. G Chir; 2007 Jan-Feb;28(1-2):20-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoid tumors: rare but important disease].
  • [Transliterated title] I tumori desmoidi intra-addominali: una patologia rara, mai importante.
  • Desmoid tumors are rare benign neoplasms with high tendency to local recurrence, and they can be divided into extra- and intra-abdominal types (mesenteric fibromatosis).
  • Six patients (3 men and 3 women) affected by extra-abdominal desmoid tumors have been treated with radical excision.
  • 1) a 55 years old man admitted for acute abdomen and submitted, in emergency, to a laparotomy with excision of a mesenteric abscess including a jejunal loop at about one meter from Treitz;.
  • 2) 52 years old man, submitted to an elective excision of a capsulated neoplasm of the little omentum, which had caused an oppressive abdominal pain.
  • In both cases the hystological diagnosis has been desmoid tumor.
  • Surgical treatment of desmoid tumors must aim at radical excision to avoid frequent recurrences (25-65%); these have stimulated the research of other kinds of treatments, since a new surgical operation itself can lead to a further recurrence.
  • Radiotherapy has been investigated with results in 79-96% of cases, antiestrogenic therapy has been used with success in 51% of patients, and high dose tamoxifen seemed to obtain a stable disease in non operable cases.
  • Non steroidal anti-inflammatory drugs have been experimented in association with tamoxifen and chemotherapy.
  • Conclusive results on the efficacy of these treatments have not been obtained yet, because of the rarity of the desmoid tumors even in greater Centres.
  • [MeSH-major] Fibromatosis, Abdominal / surgery. Mesentery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Aged. Female. Fibromatosis, Aggressive / surgery. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313728.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Noonan AM, Carney DN, McCaffrey J: Review of neoplastic brachial plexopathy at the Mater Misericordiae University Hospital, Ireland. J Clin Oncol; 2009 May 20;27(15_suppl):e20681

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20681 Background: Neoplastic brachial plexopathy (NBP) may occur with benign or malignant neoplasms.
  • Despite therapy NBP is often irreversible.
  • 18 MRIs were performed in patients with a known cancer diagnosis, 1 was performed in a patient with a benign thymoma, 1 with a neurofibroma and the remaining 17 MRIs were ordered for other conditions.
  • Of the 20 MRIs performed (18 in patients with cancer, 2 in patients with a history of benign neoplasms), 6 (30%) confirmed a diagnosis of NBP.
  • 27.8% (5/18) of patients with a diagnosis of cancer had NBP (3 had metastatic breast cancer, 2 had non-small cell lung cancer (NSCLC).
  • Median age at diagnosis was 67 years (range 35 to 86 years).
  • Radiotherapy was the treatment of choice for 5 patients with cancer diagnosis, followed by chemotherapy also for one patient.
  • Data was missing on treatment for the patient with neurofibroma.
  • CONCLUSIONS: In our series in the past 5 years, 9% (6/66) of total number of MRIs of brachial plexus performed were positive for a diagnosis of NBP.
  • NBP is devastating diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Rotunda AM, Ablon G, Kolodney MS: Lipomas treated with subcutaneous deoxycholate injections. J Am Acad Dermatol; 2005 Dec;53(6):973-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lipomas are benign neoplasms of mature fat cells.
  • Current treatments are invasive and carry the risk of scarring.
  • Tumor size, cutaneous reactions, and patients' subjective responses were recorded before and after treatment.
  • RESULTS: All lipomas decreased in size (mean area reduction, 75%; range, 37%-100%) as determined by clinical measurement (with ultrasound confirmation in one lipoma) after an average of 2.2 treatments.
  • CONCLUSIONS: Our clinical experience supports our laboratory investigations demonstrating that deoxycholate, rather than phosphatidylcholine, is the active ingredient in subcutaneously injected formulas used to treat adipose tissue.
  • This small series suggests that low concentration deoxycholate may be a relatively safe and effective treatment for small collections of fat.
  • [MeSH-major] Deoxycholic Acid / administration & dosage. Lipoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2006 Sep;32(9):1217 [16970711.001]
  • (PMID = 16310057.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 005990WHZZ / Deoxycholic Acid
  •  go-up   go-down


15. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer; 2002 Jan-Feb;12(1):62-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
  • Metallothioneins (MTs) are a group of low-molecular-weight proteins that are overexpressed in a variety of human neoplasms and are related to differentiation and prognosis in some tumor types.
  • This study investigated immunohistochemically detectable metallothionein expression in benign and malignant ovarian surface epithelial tumors of serous, mucinous, and endometrioid types.
  • MT expression was observed in 56% of carcinomas (n = 139) and in 2% of benign neoplasms (n = 81).
  • Of the malignant tumors, MT expression was found in 68% of endometrioid, 56% of mucinous, and 52% of serous neoplasms.
  • The overexpression of MT in malignant as opposed to benign ovarian surface epithelial tumors may suggest a role in tumorigenesis.
  • Analogous to the situation in endometrial carcinomas, there is a tendency toward higher expression in poorly differentiated tumors.
  • Whether high MT expression is an independent prognostic factor and increased expression indicates chemotherapy resistance in ovarian cancer, as has been previously suggested, should be determined by further studies.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Cystadenoma, Mucinous / chemistry. Cystadenoma, Serous / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cell Differentiation. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11860537.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


16. Anderson RC, Elder JB, Parsa AT, Issacson SR, Sisti MB: Radiosurgery for the treatment of recurrent central neurocytomas. Neurosurgery; 2001 Jun;48(6):1231-7; discussion 1237-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for the treatment of recurrent central neurocytomas.
  • OBJECTIVE: Central neurocytomas are benign neoplasms with neuronal differentiation typically located in the lateral ventricles of young adults.
  • Although the treatment of choice is complete surgical excision, patients may experience local recurrence.
  • Adjuvant therapy for patients with residual or recurrent tumor has included reoperation, radiotherapy, or chemotherapy.
  • To avoid the side effects of conventional radiotherapy in young patients, we present a series of patients with clear evidence of tumor progression who were treated with gamma knife radiosurgery.
  • METHODS: Four patients (ages 20-49 yr; mean, 28 yr) who presented with an intraventricular mass on magnetic resonance imaging scans and underwent craniotomy for tumor resection were reviewed retrospectively.
  • When radiographic signs of tumor progression were evident, patients were treated with radiosurgery.
  • RESULTS: Complete radiographic tumor resection was achieved in all patients.
  • Local tumor progression was detected on magnetic resonance imaging scans 9 to 25 months after surgery (median, 17.5 mo).
  • All patients achieved complete response to radiosurgery with reduction in tumor size.
  • CONCLUSION: Radiosurgery with the gamma knife unit provides safe and effective adjuvant therapy after surgical resection of central neurocytomas.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11383724.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wada I, Shimizu N, Seto Y: [Treatment of neuroendocrine tumors of the digestive tract]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1606-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of neuroendocrine tumors of the digestive tract].
  • Neuroendocrine tumors of the digestive tract are relatively rare and comprise benign and malignant tumors.
  • WHO classification system is based on recognized differences in morphology, function and clinical behavior.
  • European Neuroendocrine Tumor Society(ENETS)proposed grading system and TNM classification system with disease staging for endocrine tumors of each organ which are both valid tools for prognostic stratification.
  • The only curative therapy is the complete resection of the tumor.
  • Endoscopic submucosal dissection(ESD)or local resection can be performed in low grade and early stage tumors; on the other hand, curative resection with lymph node dissection is recommended for neuroendocrine carcinoma.
  • Combination chemotherapy, such as Etoposide+Cisplatin/Carboplatin, is useful in treating unresected neuroendocrine carcinomas.
  • Octreotide and Pasireotide (SOM230), somatostatin analogues, are reported to have the benefit of both hormonal symptom control and tumor growth suppression.
  • Development of new effective drug is expected for the treatment of neuroendocrine tumors of the digestive tract.
  • [MeSH-major] Antinematodal Agents / therapeutic use. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838017.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents
  •  go-up   go-down


18. Betz CS, Jäger HR, Brookes JA, Richards R, Leunig A, Hopper C: Interstitial photodynamic therapy for a symptom-targeted treatment of complex vascular malformations in the head and neck region. Lasers Surg Med; 2007 Aug;39(7):571-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial photodynamic therapy for a symptom-targeted treatment of complex vascular malformations in the head and neck region.
  • BACKGROUND AND OBJECTIVES: Photodynamic therapy is based on an interaction of a drug and light in oxygenated tissue.
  • The photosensitizing drug Foscan is licensed in the EU for the treatment of advanced head and neck cancer.
  • The light can be applied by surface illumination or directly into tumour tissue by optical fibres.
  • This raises the possibility of using this therapy in the treatment of benign neoplasms in the head and neck.
  • The treatments were carried out using Temoporphin (Foscan) 0.15 mg/kg; the drug-light-interval was 4 days.
  • Multiple fibres were positioned either image guided [13] or clinically [12] to ensure accurate targeting of tissue while avoiding damage of the surrounding and overlying tissue.
  • RESULTS: In all cases there was a significant reduction in the volume of abnormal tissue without damage to the overlying skin; the results were objectified using MRI-imaging, CT-volumetry and surface optical scanning.
  • Post-treatment pain and swelling were successfully controlled with steroids and a variety of analgesics (opioids and non-steroidal anti-inflammatories).
  • CONCLUSION: This minimally invasive approach to treat complex benign neoplasias seems promising.
  • The treatment is safe, effective and repeatable and merits further evaluation.
  • [MeSH-major] Mesoporphyrins / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Vascular Malformations / drug therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Head. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neck. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Vascular Malformations.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868106.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


19. Huber Z: [Surgical treatment of symptomatic surgery in children using classical techniques versus extended lesion surgery and focal lesion surgery]. Neurol Neurochir Pol; 2000;34 Suppl 8:75-84
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of symptomatic surgery in children using classical techniques versus extended lesion surgery and focal lesion surgery].
  • [Transliterated title] Chirurgiczne leczenie padaczki objawowej u dzieci metoda klasycznych operacji czy tez poszerzona lezjonektomia wraz z fokektomia.
  • In a series of 2400 children 80% had favourablly responded to medication, 60% are seizure-free and in 20% there was significant improvement in further 20% any medication has failed.
  • 200 children have been operated upon because of epilepsy resistant to pharmacological treatment., in 80 = 3% classical methods of removal of the epileptogenic substrate (lobectomies, hemisphereectomies, topectomies and disconnective techniques) have been applied.
  • In 120 cases verified symptomatic epilepsy associated with the leading symptom of untreatable attacks due to aetiological lesions as benign neoplasms, scars, angiomas, cysts lesionectomies extended by focectomies have been performed (with a seizure result of 77.6%).
  • The plasticity of the developing brain has resulted in a very impressively favourable outcome particularly in the seizure-free children as far as it concerns the intellectual level and social validation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11780592.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 20
  •  go-up   go-down


20. Szyfter W, Wierzbicka M, Jackowska J, Bartochowska A, Banaszewski J: [The schedule of intralesional papillomatosis treatment with cidofovir]. Otolaryngol Pol; 2010 Mar-Apr;64(2):98-102
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The schedule of intralesional papillomatosis treatment with cidofovir].
  • It is characterized by proliferation of benign squamous cell papillomas within the respiratory-digestive tract, predominantly the larynx.
  • Standard treatment consists of surgical excision of papillomata to maintain airway patency and voice quality.
  • For last several years cidofovir is the most contemporary adjuvant anti-viral treatment for recurrent respiratory papillomatosis and its topical use is widely described.
  • MATERIAL AND METHODS: Intralesional cidofovir therapy was given to 20 patients treated for laryngeal papillomas in the Department of Otolaryngology in Poznan between I-XII.2009.
  • The character of the lesion differed: from one anatomical site and moderate growth to four or five localizations with heavy extension.
  • The number of cidofovir injections per patient varied from one to six times and the volume of solution ranges from 1-12 ml.
  • In massive lesions injections were repeated in the same anatomical site.
  • 12 patients show remission in a place of cidofovir injection.
  • CONCLUSIONS: Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Poland. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568538.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


21. Oltmann SC, Fischer A, Barber R, Huang R, Hicks B, Garcia N: Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance. J Pediatr Surg; 2010 Jan;45(1):135-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors with neoplastic pathology (malignant and benign) were analyzed and compared with all reported cases in the literature.
  • Four malignancies (3.5%) and 26 benign neoplasms (23%) were present in this age group.
  • Malignancies consisted of serous borderline tumors (2), juvenile granulosa cell tumor (1), and dysgerminoma (1).
  • All were stage I: the former were stage IA and cured with resection alone, and 1 was a stage IB dysgerminoma, which required chemotherapy.
  • The literature yielded a total of 593 cases of operative ovarian torsion with 9 (1.5%) malignancies and 193 (33%) benign neoplasms.
  • The malignancies were juvenile granulosa cell tumor (n = 4), dysgerminoma (n = 2), serous borderline tumors (n = 2), and 1 undifferentiated adenocarcinoma.
  • Further study is needed to determine if delaying resection by weeks in those cases of persistent masses would result in tumor progression and thus change prognosis.
  • [MeSH-major] Ovarian Diseases / diagnosis. Ovarian Neoplasms / diagnosis. Torsion Abnormality / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adolescent. Adult. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Female. Granulosa Cell Tumor / diagnosis. Granulosa Cell Tumor / surgery. Humans. Incidence. Infant

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


22. Dalit A, Karen M, Alexander M: Congenital desmoid tumor of the cheek: a clinicopathological case report. Eplasty; 2009;9:e52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital desmoid tumor of the cheek: a clinicopathological case report.
  • OBJECTIVE: Desmoid tumors are rare benign neoplasms of fibroblastic origin, frequently presenting in the abdomen of adult patients.
  • Little is reported about clinical features and outcome of desmoid tumors appearing in infants and children, especially when they are located in the face.
  • METHODS: We report a girl with a desmoid tumor of her cheek, which was present at birth.
  • RESULTS: The tumor was treated by surgical excision, with no additional treatment, other than follow-up.
  • No recurrence of the tumor was witnessed 15 months following surgical excision.
  • SUMMARY: Radical surgical treatment with tumor excision, sometimes accompanied by radiotherapy, is the current standard therapy for infantile desmoid tumors.
  • Pharmacological treatment may be added in selected cases.
  • These modalities may be challenging when desmoid tumors appear in the face because of risks of facial distortion and associated growth problems.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dentomaxillofac Radiol. 2008 Mar;37(3):167-70 [18316509.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):30-8 [15599346.001]
  • [Cites] J Craniomaxillofac Surg. 2006 Apr;34(3):168-72 [16549363.001]
  • [Cites] J Pediatr Surg. 1999 Jul;34(7):1112-4 [10442602.001]
  • [Cites] J Laryngol Otol. 1997 Jul;111(7):669-70 [9282213.001]
  • [Cites] Childs Nerv Syst. 1996 Jul;12(7):409-12 [8869779.001]
  • [Cites] Ear Nose Throat J. 1993 Jul;72(7):460-7, 470-2 [8354157.001]
  • [Cites] Br J Oral Maxillofac Surg. 1992 Aug;30(4):257-62 [1510902.001]
  • [Cites] Otolaryngol Head Neck Surg. 1988 Apr;98(4):346-9 [3132692.001]
  • [Cites] Int J Oral Maxillofac Surg. 1989 Oct;18(5):264-5 [2509576.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1977 May;43(5):651-7 [266144.001]
  • [Cites] S Afr J Surg. 1971 Jul-Sep;9(3):133-40 [5138518.001]
  • [Cites] Ear Nose Throat J. 2004 Jul;83(7):481-4 [15372920.001]
  • [Cites] Kulak Burun Bogaz Ihtis Derg. 2002 Jan-Feb;9(1):59-62 [12122627.001]
  • [Cites] Eur J Surg Oncol. 2001 Dec;27(8):701-6 [11735163.001]
  • [Cites] Am J Otolaryngol. 2000 May-Jun;21(3):207-12 [10834557.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2000 Mar;117(2):118-25 [10740002.001]
  • [Cites] West Indian Med J. 2005 Oct;54(5):337-40 [16459519.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1090-9 [16015632.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Aug;63(8):1222-6 [16094595.001]
  • [Cites] Onkologie. 2004 Dec;27(6):552-6 [15591714.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 2007 Apr;108(2):153-5 [17350660.001]
  • (PMID = 20011031.001).
  • [ISSN] 1937-5719
  • [Journal-full-title] Eplasty
  • [ISO-abbreviation] Eplasty
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2779781
  •  go-up   go-down


23. Onder M, Adişen E: A new indication of botulinum toxin: leiomyoma-related pain. J Am Acad Dermatol; 2009 Feb;60(2):325-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous leiomyomas are benign neoplasms with smooth muscle differentiation.
  • They are painful tumors of the skin.
  • In the published literature, surgical excision and pharmacologic agents such as analgesics, nifedipine, phenoxybenzamine hydrochloride, gabapentin, and doxazosin have been used in the treatment of leiomyomas with varying degrees of success.
  • Our experience showed that botulinum toxin might offer a new therapeutic approach for leiomyoma by reducing the intensity and the frequency of the pain.
  • Botulinum toxin has no known systemic adverse effects, and can be combined with other treatments without concern for drug interactions.
  • Like any other medication, aside from its actual pharmacologic effect, botulinum toxin may have had a placebo effect in our patient.
  • [MeSH-major] Botulinum Toxins / therapeutic use. Leiomyomatosis / complications. Pain / drug therapy. Pain / etiology. Skin Neoplasms / complications
  • [MeSH-minor] Adult. Analgesics / therapeutic use. Drug Therapy, Combination. Female. Humans. Pain Threshold / drug effects

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150277.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; EC 3.4.24.69 / Botulinum Toxins
  •  go-up   go-down


24. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 12 males and 11 females with a median age at RT of 6.6 years (range, 2 months to 20 years).
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.
  • [MeSH-major] Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L: Major and minor salivary gland tumors. Crit Rev Oncol Hematol; 2010 May;74(2):134-48
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major and minor salivary gland tumors.
  • Malignant salivary gland tumors are rare.
  • The most common tumor site is the parotid.
  • Nutrition may be a risk factor, as well as irradiation or a long-standing histologically benign tumor that occurs at youth.
  • Painless swelling of a salivary gland should always be considered as suspicious, especially if no sign of inflammation is present.
  • Signs and symptoms related to major salivary gland tumors differ from those concerning minor salivary gland tumors, as they depend on the different location of the salivary gland.
  • Surgical excision represents the standard option in the treatment of resectable tumors of both major and minor salivary glands.
  • Neutron, heavy ions or proton radiotherapy may be a treatment option for inoperable locoregional disease.
  • Surgery, irradiation or re-irradiation are treatment options for local relapse, whereas radical neck dissection is indicated for regional relapses.
  • Metastatic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases.
  • For highly selected patients the employment of anti-androgen therapy is indicated.
  • [MeSH-major] Carcinoma. Salivary Gland Neoplasms
  • [MeSH-minor] Animals. Digestive System Surgical Procedures / adverse effects. Digestive System Surgical Procedures / methods. Humans. Neoplasm Metastasis. Neoplasm Staging / methods. Prognosis. Recurrence. Salivary Glands, Minor / pathology. Salivary Glands, Minor / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19939701.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 149
  •  go-up   go-down


26. Seow-Choen F: The management of desmoids in patients with familial adenomatous polyposis (FAP). Acta Chir Iugosl; 2008;55(3):83-7
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This risk is about 852 times the risk for the population at large.
  • Desmoids are benign neoplasms that are capable of infiltrating locally with a high risk of recurrence (25-65%) even after extirpating surgery.
  • Simple drug treatment with tamoxifen or NSAIDS like sulindac should be used as first line treatment as it carries a response in 30-50% of patients.
  • Dacarbazine-Doxorubicin chemotherapy may have dramatic response in some cases.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Fibromatosis, Aggressive / therapy

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069698.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Serbia
  • [Number-of-references] 21
  •  go-up   go-down


27. Reed SD, Cushing-Haugen KL, Daling JR, Scholes D, Schwartz SM: Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause; 2004 Mar-Apr;11(2):214-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas.
  • OBJECTIVE: Leiomyomas are common benign neoplasms.
  • Although hormone therapy is the most common and effective treatment for menopausal symptoms, little is known about its effect on leiomyomas.
  • We examined the risk of a first diagnosis of leiomyomas in peri- and postmenopausal women associated with prior use of estrogen and progestogen therapy (EPT).
  • Cases had a first diagnosis of leiomyomas confirmed by surgery or ultrasound.
  • Controls were women of the same age range without a diagnosis of leiomyomas selected at random from membership and outpatient files.
  • Adjusted odds ratios (OR) and 95% CIs were estimated using logistic regression models.
  • RESULTS: EPT use for more than 5 years was associated with a 1.7-fold increased risk of leiomyomas (95% CI, 0.9-3.3).
  • Associations with EPT use were only present among women with a body mass index less than 24 kg/m; OR (ever-use), 2.3 (95% CI, 1.2-4.3); and OR (>or= 5 years use), 4.0 (95% CI, 1.6-10.3).
  • CONCLUSION: Among peri- and postmenopausal women, prior EPT use was associated with an increased risk of a subsequent leiomyomas.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15021452.001).
  • [ISSN] 1072-3714
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD029819-04; United States / NICHD NIH HHS / HD / R01 HD029819; United States / NICHD NIH HHS / HD / R01 HD029819-04
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Progestins
  •  go-up   go-down


28. Yang W, Yu J: Immunologic function of dendritic cells in esophageal cancer. Dig Dis Sci; 2008 Jul;53(7):1739-46
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current therapy, including surgery, chemotherapy, radiotherapy, or a combination, is only to palliate the symptoms; overall the prognosis is poor.
  • Dendritic cells existing in the esophageal tissues play an important role in the host's immunosurveillance against cancer as the professional antigen-presenting cells.
  • This review concerns the immunology of dendritic cells in esophageal cancer; it describes the expression of DCs in the normal esophageal tissues and benign disease of esophagus, relations between the DCs and cancer development in esophageal cancer, and the DC-based approach to establish treatment for esophageal cancer.
  • [MeSH-major] Dendritic Cells / immunology. Esophageal Neoplasms / immunology. Esophageal Neoplasms / therapy. Immunotherapy / methods
  • [MeSH-minor] Antigens, Neoplasm / immunology. Esophagus / cytology. Humans

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080193.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Number-of-references] 49
  •  go-up   go-down


29. Larghi A, Tringali A, Lecca PG, Giordano M, Costamagna G: Management of hilar biliary strictures. Am J Gastroenterol; 2008 Feb;103(2):458-73
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary strictures at the liver hilum are caused by a heterogeneous group of benign and malignant conditions.
  • In the absence of a clear-cut benign etiology, i.e. bile duct damage during surgery, hilar biliary strictures remain a diagnostic and therapeutic challenge for which a multidisciplinary approach is often necessary.
  • A definitive diagnosis can be achieved in only 40-60% of the patients, while in all the other cases strictures are treated as though they are malignant until surgical pathology determines otherwise.
  • Surgical resection is the only treatment that prolongs survival in patients with malignant strictures.
  • Because these tumors frequently extend longitudinally via the hepatic ducts into the liver parenchyma, partial hepatic resection has been gradually added to biliary resection to ensure tumor-free surgical margins.
  • Other modalities of treatment such as radiotherapy, chemotherapy, and photodynamic therapy currently remain investigational.
  • For benign post surgical hilar strictures, surgical repair can be difficult and requires specific skills and experience.
  • As an alternative, a multi-stent technique with endoscopic placement of an increasing number of stents over time until complete resolution of the stricture has been proposed.
  • [MeSH-major] Bile Duct Neoplasms. Hepatic Duct, Common
  • [MeSH-minor] Bile Duct Diseases / diagnosis. Bile Duct Diseases / etiology. Bile Duct Diseases / therapy. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028506.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 153
  •  go-up   go-down


30. Nyckowski P, Dudek K, Skwarek A, Zieniewicz K, Pawlak J, Patkowski W, Michałowicz B, Alsharabi A, Wróblewski T, Leowska E, Paczkowska A, Ołdakowska-Jedynak U, Paczek L, Krawczyk M: Results of liver transplantation according to indications for orthotopic liver transplantation. Transplant Proc; 2003 Sep;35(6):2265-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study assessed the results of liver transplantation in patients with a variety of different indications.
  • The diagnoses were: PBC (n = 34); PSC (n = 13); elective postinflammatory cirrhosis in the course of hepatitis C (n = 29); hepatitis B (n = 16); postalcoholic cirrhosis (n = 23), autoimmune cirrhosis (n = 11); Wilson's disease (n = 6); cirrhosis of unknown etiology (n = 10); secondary biliary cirrhosis (n = 5); Budd-Chiari syndrome (n = 6); and benign liver neoplasms (n = 7).
  • In other groups it was: PBC, 91.4%; PSC, 69.2%; hepatitis C, 69.6%; hepatitis B, 55.5%; postalcoholic cirrhosis, 80%; autoimmune cirrhosis, 81.8%; Wilson's disease, 57.1%; secondary biliary cirrhosis, 40%; Budd-Chiari syndrome, 66.6%; hemochromatosis, 100%; benign neoplasms of the liver, 87.5%; and liver cysts, 100%.
  • CONCLUSIONS: Results of liver transplantation were closely related to the urgency of the procedure.
  • The best results of liver transplantation were achieved in patients transplanted on a routine basis with a diagnosis of PBC (91.4%), autoimmunologic cirrhosis (81.1%), postalcoholic cirrhosis (80%), or hemochoromatosis (100%).
  • Patients with liver insufficiency due to hepatitis B and Wilson's disease have an increased risk of graft destruction, and the rate of survival in these patients is significantly lower than in other patients.
  • [MeSH-minor] Female. Graft Rejection / drug therapy. Graft Rejection / epidemiology. History, 16th Century. Humans. Immunosuppressive Agents / therapeutic use. Male. Patient Selection. Retrospective Studies. Severity of Illness Index. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529909.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


31. Viswanathan S, George S, Ramadwar M, Shet T, Arora B, Laskar S, Qureshi S, Medhi S, Muckaden MA, Kurkure PA, Kane SV, Banavali S: Extraconal orbital tumors in children--a spectrum. Virchows Arch; 2009 Jun;454(6):703-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraconal orbital tumors in children--a spectrum.
  • We analyzed 47 specimens comprising biopsies, excision specimens, and FNAC of extraconal pediatric orbital masses (excluding retinoblastoma) accessioned in the pathology department over 5 years in a tertiary referral cancer center.
  • The chief presenting symptom was proptosis in 55.3% patients and radiologically 53.8% malignant tumors showed extraorbital extension.
  • Malignant round cell tumors (76.6%), chiefly embryonal rhabdomyosarcoma (51%), benign spindle cell neoplasms, and infectious lesions (tuberculosis, fungal infections), were seen.
  • Of the malignant tumors, those confined to the orbit achieved good treatment response and had an event-free follow-up while those with extraorbital spread had poor outcome.
  • Pediatric orbital masses range from completely treatable infectious lesions, surgically resectable benign neoplasms to aggressive malignancies requiring chemotherapy and radiotherapy.
  • Pathologists play a key role in distinguishing these on small biopsy material and expediating accurate treatment thus saving the vision or life of a patient.
  • [MeSH-major] Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Algorithms. Biomarkers, Tumor / analysis. Child. Child, Preschool. Exophthalmos / diagnosis. Female. Humans. Infant. Male. Mycoses / diagnosis. Mycoses / therapy. Rhabdomyosarcoma, Embryonal / chemistry. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / secondary. Tuberculosis / diagnosis. Tuberculosis / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2004 May;111(5):997-1008 [15121380.001]
  • [Cites] J Emerg Med. 1999 Jul-Aug;17(4):641-5 [10431954.001]
  • [Cites] J Clin Pathol. 2003 Jun;56(6):412-6 [12783965.001]
  • [Cites] Pediatr Clin North Am. 2003 Feb;50(1):149-72 [12713110.001]
  • [Cites] Acta Cytol. 2006 Jan-Feb;50(1):88-92 [16514847.001]
  • [Cites] Surv Ophthalmol. 2003 Jan-Feb;48(1):39-57 [12559326.001]
  • [Cites] Ophthalmology. 1986 Mar;93(3):379-84 [3703507.001]
  • [Cites] Neuroimaging Clin N Am. 2005 Feb;15(1):121-36 [15927864.001]
  • [Cites] Br J Ophthalmol. 1997 Dec;81(12):1084-8 [9497470.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2007 Mar-Apr;44(2):106-11 [17410962.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2008 Jul;72(7):971-5 [18499271.001]
  • [Cites] Arch Ophthalmol. 1998 Feb;116(2):243-6 [9488282.001]
  • [Cites] Am J Ophthalmol. 1978 Mar;85(3):407-18 [655220.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1807-18 [7284977.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):177-82 [8116746.001]
  • [Cites] Trans Am Ophthalmol Soc. 2001;99:133-42; discussion 142-3 [11797301.001]
  • [Cites] Clin Radiol. 1998 May;53(5):357-62 [9630275.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jun;30(6):474-7 [18525469.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):399-405 [8293407.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1777-99 [18025517.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):975-90 [1060381.001]
  • [Cites] Radiographics. 2008 Jul-Aug;28(4):1193-214 [18635637.001]
  • [Cites] Jpn J Ophthalmol. 2005 Jan-Feb;49(1):49-55 [15692775.001]
  • (PMID = 19421774.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Boujaoude J: Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma. World J Gastroenterol; 2007 Jul 21;13(27):3662-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of endoscopic ultrasound in diagnosis and therapy of pancreatic adenocarcinoma.
  • Since its advent more than 20 years ago, endoscopic ultrasound (EUS) has undergone evolution from an experimental to a diagnostic instrument and is now established as a therapeutic tool for endoscopists.
  • Endoscopic ultrasound cannot accurately distinguish benign from malignant changes in the primary lesion or lymph node on imaging alone.
  • The curved linear array echoendoscope enables the visualization of a needle as it exits from the biopsy channel in the same plane of ultrasound imaging in real time.
  • This allows the endoscopist to perform a whole range of interventional applications ranging from fine needle aspiration (FNA) of lesions surrounding the gastrointestinal tract to celiac plexus block and drainage of pancreatic pseudocyst.
  • This article reviews the current role of EUS and EUS-FNA in diagnosis, staging and interventional application of solid pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endoscopy, Digestive System / methods. Endosonography / methods. Pancreatic Neoplasms / ultrasonography. Ultrasonography, Interventional / methods
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Autonomic Nerve Block / methods. Biopsy, Fine-Needle / methods. Catheter Ablation / methods. Celiac Plexus. Cholangiography / methods. Diagnosis, Differential. Drug Delivery Systems / methods. Humans. Neoplasm Staging / methods. Photochemotherapy / methods. Predictive Value of Tests. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659723.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC4250635
  •  go-up   go-down






Advertisement